Core Viewpoint - The company is transitioning from a China-focused biopharma to a global biopharma, driven by the potential of its second-generation IO cornerstone drug PD-1/IL-2α dual antibody and the promising pipeline in oncology and other therapeutic areas [1][2]. Group 1: Key Products - The PD-1/IL-2α dual antibody IBI363 is positioned as a cornerstone drug in oncology, with significant overseas licensing potential due to its favorable competitive landscape and excellent early clinical data [2][3]. - The domestic product Masitide has received approval for weight loss indications and is expected to gain approval for diabetes indications soon, leveraging its first-mover advantage in the domestic market [2]. Group 2: Market Potential - The market for PD-1/IL-2α dual antibody is substantial, with expectations for it to advance from the IO resistant field to first-line treatment, supported by its large market size and multinational corporation demand [2][3]. - The company aims to achieve product sales revenue of 20 billion yuan by 2027, which will help solidify its domestic market position [3]. Group 3: Future Focus - The company is at a critical stage of transitioning to a global biopharma, with key elements such as overseas licensing of PD-1/IL-2α dual antibody and the development of new generation IO+ADC and early-stage FIC products in immunology and metabolism as future growth drivers [3]. - Revenue projections for 2025-2027 are 11.9 billion yuan, 15.75 billion yuan, and 20.4 billion yuan, with net profits expected to be 700 million yuan, 1.84 billion yuan, and 2.92 billion yuan respectively [3].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company is expected to see significant revenue growth, with total revenue projected to reach RMB 11.49 billion in 2025, representing a year-on-year increase of 21.96% [1] - The company has entered a commercialization phase for its chronic disease pipeline, which is anticipated to create a second growth curve alongside its oncology products [8] - The company aims to achieve a domestic sales target of RMB 20 billion by 2027 and plans to have five pipelines enter global Phase III studies by 2030 [8] - The IBI363 product, targeting immune-oncology, is highlighted for its potential breakthroughs in various patient populations and has received two FDA Fast Track Designations [8] - The report forecasts a net profit of RMB 574.47 million in 2025, with a substantial increase to RMB 3.03 billion by 2027, indicating a strong recovery and profitability trajectory [1] Financial Projections - Total revenue is projected to grow from RMB 9.42 billion in 2024 to RMB 20.09 billion by 2027, with a compound annual growth rate (CAGR) of approximately 32.36% [1] - The net profit is expected to turn positive in 2025, reaching RMB 574.47 million, and further increasing to RMB 3.03 billion by 2027 [1] - The earnings per share (EPS) is projected to improve from RMB -0.06 in 2024 to RMB 1.84 in 2027, reflecting a strong recovery in profitability [1]